Palvella Therapeutics, Inc. Common Stock (PVLA) is a publicly traded Healthcare sector company. As of October 23, 2026, PVLA trades at $125.31 with a market cap of $1.82B and a P/E ratio of -35.29. PVLA moved -0.68% today. Year to date, PVLA is +42.91%; over the trailing twelve months it is +72.38%. Its 52-week range spans $18.23 to $161.38. Analyst consensus is strong buy with an average price target of $235.90. Rallies surfaces PVLA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA awards Palvella third-year orphan grant funding for QTORIN rapamycin Phase 3 SELVA trial: Palvella Therapeutics received a third year of FDA Orphan Products Development grant funding for its Phase 3 SELVA program. The funding supports the trial and an open-label extension of QTORIN 3.9% rapamycin gel for microcystic lymphatic malformations; Palvella completed its rolling NDA submission in August 2026 and is targeting a potential U.S. launch in the first half of 2027 if approved.
| Metric | Value |
|---|---|
| Price | $125.31 |
| Market Cap | $1.82B |
| P/E Ratio | -35.29 |
| EPS | $-3.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $161.38 |
| 52-Week Low | $18.23 |
| Volume | 133.97K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.59M |
| Net Income | $-41.72M |
| Gross Margin | 0.00% |
11 analysts cover PVLA: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $235.90.